We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+0.11%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$709M
AUM Growth
+$195M
Cap. Flow
-$68.5M
Cap. Flow %
-9.65%
Top 10 Hldgs %
69.09%
Holding
206
New
48
Increased
50
Reduced
50
Closed
43

Top Buys

Rank Stock Value
1
ATER icon
Aterian
ATER
+$8.44M
2
COCP icon
Cocrystal Pharma
COCP
+$7.74M
3
RCON icon
Recon Technology
RCON
+$7.52M
4
LNAI
Lunai Bioworks
LNAI
+$5.46M
5
KRBP
Kiromic BioPharma, Inc. Common Stock
KRBP
+$4.18M

Top Sells

Rank Stock Value
1
VANI icon
Vivani Medical
VANI
+$4.81M
2
PENN icon
PENN Entertainment
PENN
+$4.24M
3
VTSI icon
VirTra
VTSI
+$3.45M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$3.42M
5
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$2.4M

Sector Composition

Rank Sector Weight
1 Healthcare 10.24%
2 Consumer Discretionary 1.47%
3 Technology 1.37%
4 Financials 1.09%
5 Consumer Staples 0.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZVRA icon
51
Zevra Therapeutics
ZVRA
$575M
$2.21M 0.31%
+172,163
New +$1.85M
STAB
52
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$2.19M 0.31%
400,080
-78,861
-16% -$425K
MTC icon
53
MMTec
MTC
$328M
$2.09M 0.29%
12,543
-4,343
-26% -$624K
IMG
54
DELISTED
CIMG Inc
IMG
$2.08M 0.29%
943
-436
-32% -$979K
NMRD
55
PUT
DELISTED
Nemaura Medical, Inc. Common Stock
NMRD
$2.08M 0.29%
2,005
+1,504
+300% +$14.4K
NMTR
56
PUT
DELISTED
9 Meters Biopharma
NMTR
$1.99M 0.28%
906
-404
-31% -$9.92K
ORMP icon
57
PUT
Oramed Pharmaceuticals
ORMP
$171M
$1.9M 0.27%
1,418
-268
-16% -$3.06K
TCDA
58
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.89M 0.27%
436,500
+81,745
+23% +$390K
ADOM
59
DELISTED
ADOMANI Inc
ADOM
$1.82M 0.26%
+6,166,711
New +$1.82M
BCLI
60
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.79M 0.25%
314
+19
+6% +$1.01K
ASXC
61
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$1.77M 0.25%
5,594
-1,365
-20% -$3.41K
AFIB
62
DELISTED
Acutus Medical Inc
AFIB
$1.75M 0.25%
103,100
-29,422
-22% -$430K
XWEL icon
63
PUT
XWELL
XWEL
$8.87M
$1.71M 0.24%
554
-94
-15% -$2.68K
LSTA icon
64
PUT
Lisata Therapeutics
LSTA
$10.6M
$1.68M 0.24%
694
-103
-13% -$2.44K
CVM.WS
65
PUT
DELISTED
Cel-Sci Corp Series S
CVM.WS
$1.66M 0.23%
1,916
+468
+32% +$406K
WIMI
66
PUT
WiMi Hologram Cloud
WIMI
$21M
$1.61M 0.23%
294
+110
+60% +$6.18K
OPTT icon
67
PUT
Ocean Power Technologies
OPTT
$38.4M
$1.5M 0.21%
4,180
+27
+0.7% +$67
AMRN
68
PUT
Amarin Corp
AMRN
$293M
$1.48M 0.21%
169
+153
+956% +$15K
AMRN
69
Amarin Corp
AMRN
$293M
$1.43M 0.2%
16,349
+7,892
+93% +$775K
ADTX
70
PUT
DELISTED
ADITXT INC
ADTX
– –
0
– –
TRIL
71
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.39M 0.2%
143,496
-56,073
-28% -$528K
BIIB icon
72
Biogen
BIIB
$30.4B
$1.39M 0.2%
+4,000
New +$1.21M
INFI
73
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.32M 0.19%
441,473
-88,527
-17% -$280K
CVM icon
74
CEL-SCI Corp
CVM
$21M
$1.26M 0.18%
+4,843
New +$3M
IKT icon
75
Inhibikase Therapeutics
IKT
$363M
$1.18M 0.17%
+70,200
New +$2.07M
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sabby Management held 206 positions worth $709M, up 38% from $514M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management withdrew a net $68.5M in Q2 2021, closing 43 positions and reducing 50 holdings. Its most notable exit was PENN Entertainment, an estimated $4.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Sabby Management opened a new position in Aterian worth $6.33M.

  • Sabby Management's largest Q2 2021 buy was Aterian: 36,083 shares worth $6.33M.
  • Sabby Management added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $2.87M increase.
  • Sabby Management's biggest Q2 2021 reduction was Vivani Medical, cutting an estimated $4.81M.
  • Sabby Management fully exited PENN Entertainment in Q2 2021, selling an estimated $4.24M.
  • Sabby Management's ten largest holdings make up 69% of its $709M portfolio in Q2 2021.
  • Sabby Management opened 48 new positions and closed 43 in Q2 2021.
  • Sabby Management's portfolio value rose 38% quarter-over-quarter to $709M.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.